LOS ANGELES, CA / ACCESSWIRE / January 12, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Agile Therapeutics, Inc. ("Agile" or the "Company") (AGRX). Investors, who purchased or otherwise acquired shares between March 9, 2016 and January 3, 2017 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the March 7, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Agile is a pharmaceutical company that makes and sells prescription female contraceptive products.

On January 3, 2017, Agile revealed new information related to its Phase 3 SECURE study assessing Agile's combined hormonal contraceptive patch product, Twirla. The FDA wanted the study after it rejected Agile's initial marketing application in 2013.

The Company stated that 2% of study participants suffered "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." Furthermore, 51.4% of subjects left the study.

When this information was revealed to the public, the value of Agile stock fell almost 64%, causing investors severe harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
https://lundinlawpc.com/

SOURCE: Lundin Law PC